Celltrion美国工厂全面启动CMO生产
This marks a significant step in Celltrion's U.
Initiated full-scale CMO production and validation for in-house products at U.S. facility.
Celltrion已在其美国Branchburg工厂全面启动Eli Lilly CMO产品的生产,此前该工厂于2026年1月前完成收购和场地准备。公司还启动了自有产品制造的验证程序,目标是建立一个完全整合的美国供应体系。此举是通过本地生产和库存来降低美国关税风险战略的一部分。
This marks a significant step in Celltrion's U.S. expansion and manufacturing strategy. By commencing production at the acquired Branchburg facility, Celltrion is enhancing its operational capabilities in a key market. The parallel validation for its own products signals a move towards greater self-sufficiency and a more integrated supply chain within the U.S. This proactive approach, including structural mitigation of tariff risks through local production, is crucial for maintaining business continuity and safeguarding shareholder value amidst potential U.S. trade policy shifts. The ability to supply locally manufactured products directly to the U.S. market strengthens Celltrion's competitive position and reduces reliance on imports, which is particularly relevant for APAC companies looking to expand their global footprint and navigate international trade complexities.
This U.S. expansion and production initiative is relevant to APAC as it demonstrates Celltrion's global strategy and its ability to establish robust manufacturing and supply chains in major international markets. Success in the U.S. can serve as a model for other APAC-based biopharmaceutical companies seeking to expand globally, highlighting the importance of localized production and risk mitigation strategies in navigating international trade policies and ensuring market access.
此信号在行业全局中的位置。
https://www.celltrion.com/en-us/company/notice/4561
阅读完整来源精选情报直达收件箱。无垃圾邮件,随时退订。
登录后可保存信号笔记。
登录